Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma (NCT07091864)

🧪 Interventions in This Study

• Best Practice (OTHER)
• Biospecimen Collection (PROCEDURE)
• Dietary Intervention (OTHER)
• Glucose Measurement (OTHER)
• Magnetic Resonance Imaging (PROCEDURE)
• Monitoring (OTHER)
• Questionnaire Administration (OTHER)
• Supportive Care (OTHER)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Presumed newly diagnosed GBM based on imaging findings consistent with GBM on brain MRI (e.g., heterogeneously enhancing mass with central necrosis and surrounding edema), as determined by the treating neuro-oncology team
2. Age ≥ 18 years at the time of consent
3. Negative serum pregnancy test within 7 days prior to registration for individuals of childbearing potential
4. Karnofsky performance status (KPS) ≥ 70 at baseline
5. Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L (performed within 14 days prior to registration)
6. Platelet count ≥ 100 × 10\^9/L (performed within 14 days prior to registration)
7. Hemoglobin ≥ 9 g/dL (performed within 14 days prior to registration)
8. Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 60 mL/min (performed within 14 days prior to registration)
9. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (performed within 14 days prior to registration)
10. Total bilirubin ≤ 1.5 × ULN (performed within 14 days prior to registration)
11. Willingness and ability to comply with CGM device use and attend dietary counseling sessions as per standard of care

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (3 Sites)

• Mayo Clinic in Arizona — Phoenix, Arizona
• Mayo Clinic in Florida — Jacksonville, Florida
• Mayo Clinic in Rochester — Rochester, Minnesota

📞 Contact the Study Coordinator

Phone: (855) 776-0015

Email: mayocliniccancerstudies@mayo.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Glioblastoma, IDH-Wildtype

• Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma — Birmingham, Alabama
• The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma — San Francisco, California
• GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma — Rochester, Minnesota
• WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma — Chicago, Illinois
• Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma — Scottsdale, Arizona

Explore by condition: All Glioblastoma, IDH-Wildtype clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.